PDCD1LG2 and sarcoma: Carcinosarcoma, endometrial leiomyosarcoma, or other high grade sarcomas, or endometrial stromal sarcomasAdditional malignancies that have progressed or required active treatment in the last 3 years†Gastrointestinal conditions that might affect absorption of lenvatinibActive infection requiring systemic treatmentPrevious therapy with any treatment targeting vascular endothelial growth factor-directed angiogenesis; anti-PD-1, anti-PD-L1, or anti-PD-L2 agents; or any agent directed at another stimulatory or co-inhibitory T cell receptorInadequate organ function